Ramanan Laxminarayan

Director and Senior Fellow

Ramanan Laxminarayan directs the Center for Disease Dynamics, Economics & Policy. He is also a Senior Research Scholar and Lecturer at Princeton University. His research deals with the integration of epidemiological models of infectious diseases and drug resistance into the economic analysis of public health problems. He has worked to improve understanding of drug resistance as a problem of managing a shared global resource.

Laxminarayan has worked with the World Health Organization (WHO) and the World Bank on evaluating malaria treatment policy, vaccination strategies, the economic burden of tuberculosis, and control of non-communicable diseases. He has served on a number of advisory committees at WHO, Centers for Disease Control and Prevention, and the Institute of Medicine. In 2003-04, he served on the National Academy ofScience/Institute of Medicine Committee on the Economics ofAntimalarial Drugs and subsequently helped create the Affordable Medicines Facility for malaria, a novel financing mechanism for antimalarials. His work has been covered in major media outlets including Associated Press, BBC, CNN, the Economist, LA Times, NBC,NPR, Reuters, Science, Wall Street Journal, and National Journal.

 

Publications

12 Sep 2014

What are the best strategies for conserving the natural resource of antibiotic effectiveness?

10 Aug 2014

How would increasing immunization coverage and introducing a rotavirus vaccine affect the disease and financial burden of vaccine-preventable illnesses in India?

10 Apr 2014

Objectives: To estimate the epidemiological and financial benefits and the distributional consequences of policy interventions for coronary heart disease (CHD) and secondary...

5 Mar 2014

How do incentives affect countries' decisions to report infectious disesase outbreaks?

11 Feb 2014

Universal public finance (UPF) for health interventions entail consequences in a number of domains. UPF increases intervention uptake and consequent health gains; generates financial consequences...

28 Feb 2014

How prevalent is S. epidermis, the most common Coagulase-negative staphylococci (CoNS) pathogen, and what are trends in its resistance profile? How does this compare to all...